Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease

NCT00359944 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT00359944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00359944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
September 30, 2008
Enrollment
171 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease